IBM is pushing hard against the boundaries of data processing andintegration in a way that ultimately could affect everyone's health and well-being.
Through a technology license with Incyte Genomics Inc., IBM is applying its DiscoveryLink technology to the challenge of sifting mountains of genetic data to better identify the causes of diseases and aid in developing cures. DiscoveryLink's data- integration technology will be integrated with Incyte's Genomic Knowledge Platform.
Using DiscoveryLink and Incyte's platform, researchers will have an easier time with the staggeringly complex task of accessing and analyzing biological data to uncover patterns and associations. Incyte's new software integrates data from multiple genomic-analysis tools and varied data formats to let researchers see patterns and data dependencies that are difficult or impossible to comprehend using isolated tools. Data such as DNA sequence, gene expression, and genetic variations will be able to be combined and interpreted for patterns and associations that could well lead to unexpected discoveries.
IBM says it has earmarked $100 million to develop advanced research technology for biotechnology, genomic, E-health, pharmaceutical, and agri-science industries. "What's needed in this field is a knowledge-management system that lets researchers query across any and all of this data, write complex queries, and have the data appear to be coming from a common repository," says Caroline Kovac, VP of IBM Life Sciences. Data warehousing doesn't do all that well with disparate data, and it also has a rigid schema, so you can't add new sources very easily. DiscoveryLink helps researchers integrate data in a flexible and scalable way.